医疗集团弗雷泽尼乌斯周三在公布超预期的第三季度业绩后上调了全年预期，Kabi和Helios两大部门的强劲表现支撑了盈利。
Healthcare group Fresenius raised full-year expectations on Wednesday after reporting higher-than-anticipated third-quarter results, as strong performance at the Kabi and Helios divisions supported earnings.
公司现在预计，2026年不变货币核心每股收益（EPS）增速将达到此前10%-15%预测区间的上限，息税前利润（EBIT）利润率将高于11.5%，此前预期为11.5%左右。
The company now expects 2026 constant-currency core earnings per share (EPS) growth of at the upper-end of its 10%-15% forecast, and an earnings before interests and taxes (EBIT) margin above 11.5%, compared with around 11.5% previously.
这是弗雷泽尼乌斯今年第二次上调展望，此前曾在8月提高核心EPS目标，旨在在CEO Michael Sen的转型战略下提升盈利能力并减少债务。
The latest upgrade is Fresenius' second this year, after raising its core EPS target in August, as it seeks to improve profitability and reduce debt under CEO Michael Sen's turnaround strategy.
弗雷泽尼乌斯的业绩与其前子公司弗雷泽尼乌斯医疗护理（FMEG.DE）形成对比，后者在连续第三个季度美国治疗量下降后下调了运营收入展望，弗雷泽尼乌斯仍持有该透析专家25%的股份。
Fresenius' results contrast those of former unit Fresenius Medical Care (FMEG.DE), in which it still owns a 25% stake, after the dialysis specialist cut its operating income outlook following a third consecutive quarterly decline in US treatment volumes.